|
Volumn 104, Issue 9, 2007, Pages 3019-3020
|
Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ADENOSINE TRIPHOSPHATE;
ADENYLATE KINASE;
ANTIDIABETIC AGENT;
ANTIPARKINSON AGENT;
ARIPIPRAZOLE;
ATYPICAL ANTIPSYCHOTIC AGENT;
BETAHISTINE;
CHLORPROMAZINE;
CLOZAPINE;
HALOPERIDOL;
HISTAMINE H1 RECEPTOR;
HISTAMINE H1 RECEPTOR AGONIST;
INSULIN;
LEPTIN;
LEVODOPA;
MELPERONE;
METFORMIN;
OLANZAPINE;
PALIPERIDONE;
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST;
QUETIAPINE;
RISPERIDONE;
SEROTONIN 2C RECEPTOR;
ZIPRASIDONE;
AGRANULOCYTOSIS;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
BODY WEIGHT;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
COST EFFECTIVENESS ANALYSIS;
DIABETES MELLITUS;
DIABETIC KETOACIDOSIS;
DRUG COST;
DRUG EFFICACY;
DRUG INDUCED DISEASE;
ENZYME PHOSPHORYLATION;
EXTRAPYRAMIDAL SYMPTOM;
HUMAN;
HYPERLIPIDEMIA;
HYPERTRIGLYCERIDEMIA;
HYPOTHALAMUS;
INSULIN RESISTANCE;
ISCHEMIC HEART DISEASE;
MENTAL DISEASE;
METABOLIC DISORDER;
MOUSE;
NONHUMAN;
NOTE;
OBESITY;
PARKINSON DISEASE;
PRIORITY JOURNAL;
PSYCHOPHARMACOTHERAPY;
PSYCHOSIS;
SCHIZOPHRENIA;
SIDE EFFECT;
TRIACYLGLYCEROL BLOOD LEVEL;
WEIGHT GAIN;
ANTIPSYCHOTIC AGENTS;
BENZODIAZEPINES;
DIBENZOTHIAZEPINES;
HUMANS;
HYPOTHALAMUS;
PROTEIN KINASES;
RISPERIDONE;
SCHIZOPHRENIA;
WEIGHT GAIN;
|
EID: 33847685647
PISSN: 00278424
EISSN: None
Source Type: Journal
DOI: 10.1073/pnas.0700090104 Document Type: Note |
Times cited : (20)
|
References (26)
|